La vendita allo scoperto per ALX Oncology Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ALX Oncology Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Report sulle vendite allo scoperto

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

Earnings

News

BMWYY

BMW Group Q3 2024 Revenue €32.4B Vs €38.46B YoY

2024 Earnings Guidance and Outlook
<ul>
<li>Avista Corp. is lowering its 2024 consolidated earnings guidance to a range of $2.26 to $2.46 per diluted share as a result of lower-than-expected valuations at our other businesses.</li>
<li>Including the expected ERM impact of negative $0.08 per diluted share, we expect Avista Utilities to contribute near the low end of the range of $2.23 to $2.39 per diluted share in 2024.</li>
<li>We expect AEL&amp;P to contribute in the range of $0.09 to $0.11 per diluted share in 2024.</li>
<li>Valuations in the private equity markets have not recovered to the degree we expected. As a result, we now expect our other businesses to have a net loss in the range of $0.06 to $0.04 per diluted share in 2024.</li>
<li>Our guidance does not include the effect of unusual or non-recurring items until the effects are probable. Various factors could cause actual results to differ materially from our expectations, including our earnings guidance. Please refer to our 10-K for 2023, our 10-Q for the third quarter of 2024, and the cautionary statements below, for a full discussion of these factors.</li>
</ul>

Guidance

Avista Corp Lowers Its 2024 Guidance: Now Sees EPS Of $2.26-$2.46 (Prior $2.36-$2.56) Vs. $2.44 Est.

Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. The company reported quarterly sales of $1.34 million which missed the analyst consensus estimate of $1.86 million by 28.03 percent. This is a 71.25 percent decrease over sales of $4.66 million the same period last year.

ABUS

Arbutus Biopharma Q3 2024 GAAP EPS $(0.10) Misses $(0.09) Estimate, Sales $1.34M Miss $1.86M Estimate

Baird analyst David Leiker maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Neutral and raises the price target from $330 to $372.

Price Target

Analyst Ratings

Baird Maintains Neutral on Cummins, Raises Price Target to $372

FPAY

FlexShopper Announced A Strategic Partnership With The Aftermarket Auto Parts Alliance To Expand Its Payment Solutions To Over 7,800 Locations Representing A 246% Increase From The Beginning Of 2024

Baird analyst Ghansham Panjabi maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $150 to $110.

Baird Maintains Outperform on Celanese, Lowers Price Target to $110

Barclays analyst Jiong Shao initiates coverage on Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with a Overweight rating and announces Price Target of $19.

Initiation

VIPS

Barclays Initiates Coverage On Vipshop Holdings with Overweight Rating, Announces Price Target of $19

PSTV

Plus Therapeutics And SpectronRx Announced The Signing Of A Manufacturing Services Agreement For The Production Of Rhenium (186Re) Obisbemeda, An Innovative Radiotherapy For CNS Cancers, Including Leptomeningeal Metastases And Recurrent Glioblastoma

Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(1.99) by 38.19 percent. The company reported quarterly sales of $302.000 thousand which beat the analyst consensus estimate of $296.000 thousand by 2.03 percent. This is a 35.47 percent decrease over sales of $468.000 thousand the same period last year.

Earnings Beats

Earnings Misses

PRAX

Praxis Precision Medicine Q3 2024 GAAP EPS $(2.75) Misses $(1.99) Estimate, Sales $302.000K Beat $296.000K Estimate

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

LNTH

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and raises the price target from $18 to $20.

TRDA

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Raises Price Target to $20

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.28) by 14.84 percent. The company reported quarterly sales of $58.409 million which missed the analyst consensus estimate of $58.557 million by 0.25 percent. This is a 9.75 percent decrease over sales of $64.718 million the same period last year.

EHTH

eHealth Q3 2024 Adj. EPS $(1.47) Misses $(1.28) Estimate, Sales $58.409M Miss $58.557M Estimate

For the fourth quarter of 2024, the Company expects revenues to be in the range of $58 million to $63 million and adjusted EBITDA margin between 12% to 16%.

KRNT

Kornit Digital Expects Q4 2024 Revenues Of $58M-$63M Vs. $50.468M Consensus; Sees Adjusted EBITDA Margin Of 12% to 16%

OESX

Orion Expects FY25 Revenue Growth Outlook Of Approximately 10% And Expects Second Half Revenue To Be More Weighted To The Fourth Quarter

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) affirms FY2024 sales outlook from $470.00 million-495.00 million to $470.00 million-495.00 million.

eHealth Affirms FY2024 Sales Guidance to $470.00M-495.00M  VS Est. 483.54M

Morgan Stanley analyst Thomas Yeh maintains Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) with a Overweight and lowers the price target from $9 to $8.

LION

Morgan Stanley Maintains Overweight on Lionsgate Studios, Lowers Price Target to $8

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.41 per share. This is a 22.64 percent decrease over earnings of $0.53 per share from the same period last year. The company reported $111.92 million in sales this quarter. This is a 10.47 percent decrease over sales of $125.00 million the same period last year.

Genie Energy Q3 EPS $0.41 Down From $0.53 YoY, Sales $111.92M Down From $125.00M YoY

Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.07 by 57.14 percent. The company reported quarterly sales of $50.732 million which beat the analyst consensus estimate of $50.468 million by 0.52 percent. This is a 14.34 percent decrease over sales of $59.224 million the same period last year.

Kornit Digital Q3 2024 Adj. EPS $0.11 Beats $0.07 Estimate, Sales $50.732M Beat $50.468M Estimate

Barclays analyst Jiong Shao initiates coverage on Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) with a Overweight rating and announces Price Target of $16.

Barclays Initiates Coverage On Tencent Music Enter Gr with Overweight Rating, Announces Price Target of $16

MCFT

MasterCraft Boat Hldgs Q1 2025 Adj. EPS $0.12 Beats $0.03 Estimate, Sales $65.400M Beat $61.181M Estimate

ALX Oncology Holdings ( ($ALXO) ) has shared an update. Sophia Randolph, the Chief Medical Officer of ALX Oncology Holdings Inc., has announced her...

ALX Oncology CMO Sophia Randolph Announces Resignation

Warning: ALXO is at high risk of performing badly

ALXO

Press Releases

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Health Care

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Management

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Comments

ALX Oncology Holdings

Vendite allo scoperto

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO